Staphylococcus aureus Bacteraemia Network Adaptive Platform Trial (SNAP)

The Staphylococcus aureus bacteraemia Network Adaptive Platform trial (SNAP) is designed to evaluate clinical outcomes in patients diagnosed with this condition. The primary objective is to assess the efficacy of various therapeutic interventions within an adaptive platform framework. This approach is clinically relevant for determining the most effective treatment strategies to manage systemic infections caused by Staphylococcus aureus. There are no secondary objectives specified in the provided documentation.

This clinical trial involves a total of 10,000 participants. The study population consists of patients diagnosed with Staphylococcus aureus bacteraemia. The cohort includes both male and female individuals. Based on the provided age range codes, the participants fall within specific age categories. The sponsor did not provide additional information regarding lifestyle considerations or specific selection processes.

The Staphylococcus aureus Network Adaptive Platform trial (SNAP) is a phase 4 clinical study designed to investigate therapeutic interventions for Staphylococcus aureus bacteraemia. The research utilizes an adaptive platform trial methodology. The clinical sequence begins with a screening visit to assess eligibility. Following enrollment, participants undergo scheduled follow-up visits to monitor clinical outcomes and safety. The process concludes with an end-of-study visit. Total participant involvement is determined by the individual study trajectory and clinical requirements. The trial may be terminated early if predefined safety criteria or efficacy thresholds are met. The estimated recruitment period for this study extends from June 2026 to June 2029.

The clinical trial is designed to evaluate the efficacy of the intervention in subjects diagnosed with Staphylococcus aureus bacteraemia. As no specific efficacy parameters, assessment tools, or measurement schedules were provided in the source data, no methods for evaluating clinical response or therapeutic outcomes are specified.